Multiple Sclerosis
-
Multiple Sclerosis
Case Management Services to Meet the Complex Needs of Patients with Multiple Sclerosis in the Community—The Successes and Challenges of a Unique Program from the National Multiple Sclerosis Society
Rosalind Kalb , Kathleen Costello , Linda GuiodUS Neurology. 2019;15(1):27–31 -
Multiple Sclerosis
Monoclonal Antibody Therapy and Long-term Outcomes in Multiple Sclerosis – The Challenge of Treatment Optimisation
Antonio Scalfari, Paolo A MuraroEuropean Neurological Review. 2018;13(2):78–85 DOI: https://doi.org/10.17925/ENR.2018.13.2.78 -
Multiple Sclerosis
Falls Among Wheelchair and Scooter Users with Multiple Sclerosis—A Review
Laura A Rice, Libak Abou, Toni Van Denend, Elizabeth W Peterson, Jacob J SosnoffUS Neurology. 2018;14(2):82–7 DOI: https://doi.org/10.17925/USN.2018.14.2.82 -
Multiple Sclerosis
Updated American Academy Guidelines on the Use of Disease-modifying Therapies in Multiple Sclerosis—What’s New?
Alexander Rae-GrantUS Neurology. 2018;14(2):76–7 DOI: https://doi.org/10.17925/USN.2018.14.2.76 -
Multiple Sclerosis
Importance of Cognitive Screening and Management in Multiple Sclerosis Care—Reflection on the Recent Recommendations
Rosalind KalbUS Neurology. 2018;14(2):73–5 DOI: https://doi.org/10.17925/USN.2018.14.2.73 -
Multiple Sclerosis
Sphingosine-1-phosphate Receptor Modulators in Multiple Sclerosis
Patrick VermerschEuropean Neurological Review. 2018;13(1):25–30 DOI: https://doi.org/10.17925/ENR.2018.13.1.25 -
Multiple Sclerosis
Cognitive Assessment in Multiple Sclerosis
Dawn LangdonEuropean Neurological Review. 2018;13(1):12–3 DOI: https://doi.org/10.17925/ENR.2018.13.1.12
